Framingham score, renal dysfunction, and cardiovascular risk in liver transplant patients

Cardiovascular (CV) events represent major impediments to the long‐term survival of liver transplantation (LT) patients. The aim of this study was to assess whether the Framingham risk score (FRS) at transplantation can predict the development of post‐LT cardiovascular events (CVEs). Patients transp...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Liver transplantation 2015-06, Vol.21 (6), p.812-822
Hauptverfasser: Di Maira, Tommaso, Rubin, Angel, Puchades, Lorena, Aguilera, Victoria, Vinaixa, Carmen, Garcia, Maria, De Maria, Nicola, Villa, Erica, Lopez‐Andujar, Rafael, San Juan, Fernando, Montalva, Eva, Perez, Judith, Prieto, Martin, Berenguer, Marina
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 822
container_issue 6
container_start_page 812
container_title Liver transplantation
container_volume 21
creator Di Maira, Tommaso
Rubin, Angel
Puchades, Lorena
Aguilera, Victoria
Vinaixa, Carmen
Garcia, Maria
De Maria, Nicola
Villa, Erica
Lopez‐Andujar, Rafael
San Juan, Fernando
Montalva, Eva
Perez, Judith
Prieto, Martin
Berenguer, Marina
description Cardiovascular (CV) events represent major impediments to the long‐term survival of liver transplantation (LT) patients. The aim of this study was to assess whether the Framingham risk score (FRS) at transplantation can predict the development of post‐LT cardiovascular events (CVEs). Patients transplanted between 2006 and 2008 were included. Baseline features, CV risk factors, and CVEs occurring after LT (ischemic heart disease, stroke, heart failure, de novo arrhythmias, and peripheral arterial disease) were recorded. In total, 250 patients (69.6% men) with a median age of 56 years (range, 18‐68 years) were included. At transplantation, 34.4%, 34.4%, and 33.2% of patients, respectively, had a low, moderate, and high FRS with a median FRS of 14.9 (range, 0.09‐30); 14.4% of LT recipients developed at least 1 CVE at a median of 2.619 years (range, 0.006‐6.945 years). In the univariate analysis, factors associated with the development of CVEs were the continuous FRS at LT (P = 0.003), age (P = 0.007), creatinine clearance [estimated glomerular filtration rate (eGFR); P = 0.020], and mycophenolate mofetil use at discharge (P = 0.011). In the multivariate analysis, only the eGFR [hazard ratio (HR), 0.98; 95% confidence interval (CI), 0.97‐1.00; P = 0.009] and FRS (HR, 1.06; 95% CI, 1.02‐1.10; P = 0.002) remained in the model. Moreover, an association was also found between the FRS and overall survival (P = 0.004) with 5‐year survival rates of 82.5%, 77.8%, and 61.4% for the low‐, moderate‐, and high‐risk groups, respectively. Continuous FRS, eGFR, and hepatitis C virus infection were independent risk factors for overall mortality. In our series, the FRS and eGFR at LT were able to predict the development of post‐LT CVEs and poor outcomes. Liver Transpl 21:812‐822, 2015. © 2015 AASLD.
doi_str_mv 10.1002/lt.24128
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1803452150</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3694893571</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3498-7843c9539ceadd4a4fa93361c42820fb7a48cd501059a4efae47aacd943d64eb3</originalsourceid><addsrcrecordid>eNp1kMtKxDAUQIMoOj7AL5CAGxd2zKttspTBFwy4GReuyp0k1Wiajkk7Mn9vdUYFwdW9i8Ph3oPQMSVjSgi78N2YCcrkFhrRnJVZIUq-_bMX-R7aT-mFEEpzRXbRHiu5KiTjI_R4HaFx4ekZGpx0G-05jjaAx2aV6j7ozrXhHEMwWEM0rl1C0r2HiKNLr9gF7N3SRtxFCGnhIXR4AZ2zoUuHaKcGn-zRZh6gh-ur2eQ2m97f3E0up5nmQsmslIJrlXOlLRgjQNSgOC-oFkwyUs9LEFKbnFCSKxC2BitKAG2U4KYQds4P0Nnau4jtW29TVzUuaeuHY2zbp4pKwkXOaE4G9PQP-tL2cfh2oArJiSKFlL9CHduUoq2rRXQNxFVFSfWZu_Jd9ZV7QE82wn7eWPMDfvcdgGwNvDtvV_-KqulsLfwADuyIsQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1683090688</pqid></control><display><type>article</type><title>Framingham score, renal dysfunction, and cardiovascular risk in liver transplant patients</title><source>MEDLINE</source><source>Wiley Online Library All Journals</source><source>Alma/SFX Local Collection</source><creator>Di Maira, Tommaso ; Rubin, Angel ; Puchades, Lorena ; Aguilera, Victoria ; Vinaixa, Carmen ; Garcia, Maria ; De Maria, Nicola ; Villa, Erica ; Lopez‐Andujar, Rafael ; San Juan, Fernando ; Montalva, Eva ; Perez, Judith ; Prieto, Martin ; Berenguer, Marina</creator><creatorcontrib>Di Maira, Tommaso ; Rubin, Angel ; Puchades, Lorena ; Aguilera, Victoria ; Vinaixa, Carmen ; Garcia, Maria ; De Maria, Nicola ; Villa, Erica ; Lopez‐Andujar, Rafael ; San Juan, Fernando ; Montalva, Eva ; Perez, Judith ; Prieto, Martin ; Berenguer, Marina</creatorcontrib><description>Cardiovascular (CV) events represent major impediments to the long‐term survival of liver transplantation (LT) patients. The aim of this study was to assess whether the Framingham risk score (FRS) at transplantation can predict the development of post‐LT cardiovascular events (CVEs). Patients transplanted between 2006 and 2008 were included. Baseline features, CV risk factors, and CVEs occurring after LT (ischemic heart disease, stroke, heart failure, de novo arrhythmias, and peripheral arterial disease) were recorded. In total, 250 patients (69.6% men) with a median age of 56 years (range, 18‐68 years) were included. At transplantation, 34.4%, 34.4%, and 33.2% of patients, respectively, had a low, moderate, and high FRS with a median FRS of 14.9 (range, 0.09‐30); 14.4% of LT recipients developed at least 1 CVE at a median of 2.619 years (range, 0.006‐6.945 years). In the univariate analysis, factors associated with the development of CVEs were the continuous FRS at LT (P = 0.003), age (P = 0.007), creatinine clearance [estimated glomerular filtration rate (eGFR); P = 0.020], and mycophenolate mofetil use at discharge (P = 0.011). In the multivariate analysis, only the eGFR [hazard ratio (HR), 0.98; 95% confidence interval (CI), 0.97‐1.00; P = 0.009] and FRS (HR, 1.06; 95% CI, 1.02‐1.10; P = 0.002) remained in the model. Moreover, an association was also found between the FRS and overall survival (P = 0.004) with 5‐year survival rates of 82.5%, 77.8%, and 61.4% for the low‐, moderate‐, and high‐risk groups, respectively. Continuous FRS, eGFR, and hepatitis C virus infection were independent risk factors for overall mortality. In our series, the FRS and eGFR at LT were able to predict the development of post‐LT CVEs and poor outcomes. Liver Transpl 21:812‐822, 2015. © 2015 AASLD.</description><identifier>ISSN: 1527-6465</identifier><identifier>EISSN: 1527-6473</identifier><identifier>DOI: 10.1002/lt.24128</identifier><identifier>PMID: 27396823</identifier><identifier>CODEN: LITRFO</identifier><language>eng</language><publisher>United States: Wolters Kluwer Health, Inc</publisher><subject>Adolescent ; Adult ; Aged ; Cardiovascular Diseases - diagnosis ; Cardiovascular Diseases - epidemiology ; Cardiovascular Diseases - mortality ; Female ; Glomerular Filtration Rate ; Hepatitis C - epidemiology ; Humans ; Kaplan-Meier Estimate ; Kidney - physiopathology ; Kidney Diseases - diagnosis ; Kidney Diseases - epidemiology ; Kidney Diseases - mortality ; Kidney Diseases - physiopathology ; Liver Transplantation - adverse effects ; Liver Transplantation - mortality ; Logistic Models ; Male ; Middle Aged ; Multivariate Analysis ; Proportional Hazards Models ; Retrospective Studies ; Risk Assessment ; Risk Factors ; Spain - epidemiology ; Time Factors ; Transplant Recipients ; Treatment Outcome ; Young Adult</subject><ispartof>Liver transplantation, 2015-06, Vol.21 (6), p.812-822</ispartof><rights>2015 American Association for the Study of Liver Diseases</rights><rights>2015 American Association for the Study of Liver Diseases.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3498-7843c9539ceadd4a4fa93361c42820fb7a48cd501059a4efae47aacd943d64eb3</citedby><cites>FETCH-LOGICAL-c3498-7843c9539ceadd4a4fa93361c42820fb7a48cd501059a4efae47aacd943d64eb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Flt.24128$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Flt.24128$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1416,27923,27924,45573,45574</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27396823$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Di Maira, Tommaso</creatorcontrib><creatorcontrib>Rubin, Angel</creatorcontrib><creatorcontrib>Puchades, Lorena</creatorcontrib><creatorcontrib>Aguilera, Victoria</creatorcontrib><creatorcontrib>Vinaixa, Carmen</creatorcontrib><creatorcontrib>Garcia, Maria</creatorcontrib><creatorcontrib>De Maria, Nicola</creatorcontrib><creatorcontrib>Villa, Erica</creatorcontrib><creatorcontrib>Lopez‐Andujar, Rafael</creatorcontrib><creatorcontrib>San Juan, Fernando</creatorcontrib><creatorcontrib>Montalva, Eva</creatorcontrib><creatorcontrib>Perez, Judith</creatorcontrib><creatorcontrib>Prieto, Martin</creatorcontrib><creatorcontrib>Berenguer, Marina</creatorcontrib><title>Framingham score, renal dysfunction, and cardiovascular risk in liver transplant patients</title><title>Liver transplantation</title><addtitle>Liver Transpl</addtitle><description>Cardiovascular (CV) events represent major impediments to the long‐term survival of liver transplantation (LT) patients. The aim of this study was to assess whether the Framingham risk score (FRS) at transplantation can predict the development of post‐LT cardiovascular events (CVEs). Patients transplanted between 2006 and 2008 were included. Baseline features, CV risk factors, and CVEs occurring after LT (ischemic heart disease, stroke, heart failure, de novo arrhythmias, and peripheral arterial disease) were recorded. In total, 250 patients (69.6% men) with a median age of 56 years (range, 18‐68 years) were included. At transplantation, 34.4%, 34.4%, and 33.2% of patients, respectively, had a low, moderate, and high FRS with a median FRS of 14.9 (range, 0.09‐30); 14.4% of LT recipients developed at least 1 CVE at a median of 2.619 years (range, 0.006‐6.945 years). In the univariate analysis, factors associated with the development of CVEs were the continuous FRS at LT (P = 0.003), age (P = 0.007), creatinine clearance [estimated glomerular filtration rate (eGFR); P = 0.020], and mycophenolate mofetil use at discharge (P = 0.011). In the multivariate analysis, only the eGFR [hazard ratio (HR), 0.98; 95% confidence interval (CI), 0.97‐1.00; P = 0.009] and FRS (HR, 1.06; 95% CI, 1.02‐1.10; P = 0.002) remained in the model. Moreover, an association was also found between the FRS and overall survival (P = 0.004) with 5‐year survival rates of 82.5%, 77.8%, and 61.4% for the low‐, moderate‐, and high‐risk groups, respectively. Continuous FRS, eGFR, and hepatitis C virus infection were independent risk factors for overall mortality. In our series, the FRS and eGFR at LT were able to predict the development of post‐LT CVEs and poor outcomes. Liver Transpl 21:812‐822, 2015. © 2015 AASLD.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Cardiovascular Diseases - diagnosis</subject><subject>Cardiovascular Diseases - epidemiology</subject><subject>Cardiovascular Diseases - mortality</subject><subject>Female</subject><subject>Glomerular Filtration Rate</subject><subject>Hepatitis C - epidemiology</subject><subject>Humans</subject><subject>Kaplan-Meier Estimate</subject><subject>Kidney - physiopathology</subject><subject>Kidney Diseases - diagnosis</subject><subject>Kidney Diseases - epidemiology</subject><subject>Kidney Diseases - mortality</subject><subject>Kidney Diseases - physiopathology</subject><subject>Liver Transplantation - adverse effects</subject><subject>Liver Transplantation - mortality</subject><subject>Logistic Models</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Proportional Hazards Models</subject><subject>Retrospective Studies</subject><subject>Risk Assessment</subject><subject>Risk Factors</subject><subject>Spain - epidemiology</subject><subject>Time Factors</subject><subject>Transplant Recipients</subject><subject>Treatment Outcome</subject><subject>Young Adult</subject><issn>1527-6465</issn><issn>1527-6473</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kMtKxDAUQIMoOj7AL5CAGxd2zKttspTBFwy4GReuyp0k1Wiajkk7Mn9vdUYFwdW9i8Ph3oPQMSVjSgi78N2YCcrkFhrRnJVZIUq-_bMX-R7aT-mFEEpzRXbRHiu5KiTjI_R4HaFx4ekZGpx0G-05jjaAx2aV6j7ozrXhHEMwWEM0rl1C0r2HiKNLr9gF7N3SRtxFCGnhIXR4AZ2zoUuHaKcGn-zRZh6gh-ur2eQ2m97f3E0up5nmQsmslIJrlXOlLRgjQNSgOC-oFkwyUs9LEFKbnFCSKxC2BitKAG2U4KYQds4P0Nnau4jtW29TVzUuaeuHY2zbp4pKwkXOaE4G9PQP-tL2cfh2oArJiSKFlL9CHduUoq2rRXQNxFVFSfWZu_Jd9ZV7QE82wn7eWPMDfvcdgGwNvDtvV_-KqulsLfwADuyIsQ</recordid><startdate>201506</startdate><enddate>201506</enddate><creator>Di Maira, Tommaso</creator><creator>Rubin, Angel</creator><creator>Puchades, Lorena</creator><creator>Aguilera, Victoria</creator><creator>Vinaixa, Carmen</creator><creator>Garcia, Maria</creator><creator>De Maria, Nicola</creator><creator>Villa, Erica</creator><creator>Lopez‐Andujar, Rafael</creator><creator>San Juan, Fernando</creator><creator>Montalva, Eva</creator><creator>Perez, Judith</creator><creator>Prieto, Martin</creator><creator>Berenguer, Marina</creator><general>Wolters Kluwer Health, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>201506</creationdate><title>Framingham score, renal dysfunction, and cardiovascular risk in liver transplant patients</title><author>Di Maira, Tommaso ; Rubin, Angel ; Puchades, Lorena ; Aguilera, Victoria ; Vinaixa, Carmen ; Garcia, Maria ; De Maria, Nicola ; Villa, Erica ; Lopez‐Andujar, Rafael ; San Juan, Fernando ; Montalva, Eva ; Perez, Judith ; Prieto, Martin ; Berenguer, Marina</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3498-7843c9539ceadd4a4fa93361c42820fb7a48cd501059a4efae47aacd943d64eb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Cardiovascular Diseases - diagnosis</topic><topic>Cardiovascular Diseases - epidemiology</topic><topic>Cardiovascular Diseases - mortality</topic><topic>Female</topic><topic>Glomerular Filtration Rate</topic><topic>Hepatitis C - epidemiology</topic><topic>Humans</topic><topic>Kaplan-Meier Estimate</topic><topic>Kidney - physiopathology</topic><topic>Kidney Diseases - diagnosis</topic><topic>Kidney Diseases - epidemiology</topic><topic>Kidney Diseases - mortality</topic><topic>Kidney Diseases - physiopathology</topic><topic>Liver Transplantation - adverse effects</topic><topic>Liver Transplantation - mortality</topic><topic>Logistic Models</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Proportional Hazards Models</topic><topic>Retrospective Studies</topic><topic>Risk Assessment</topic><topic>Risk Factors</topic><topic>Spain - epidemiology</topic><topic>Time Factors</topic><topic>Transplant Recipients</topic><topic>Treatment Outcome</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Di Maira, Tommaso</creatorcontrib><creatorcontrib>Rubin, Angel</creatorcontrib><creatorcontrib>Puchades, Lorena</creatorcontrib><creatorcontrib>Aguilera, Victoria</creatorcontrib><creatorcontrib>Vinaixa, Carmen</creatorcontrib><creatorcontrib>Garcia, Maria</creatorcontrib><creatorcontrib>De Maria, Nicola</creatorcontrib><creatorcontrib>Villa, Erica</creatorcontrib><creatorcontrib>Lopez‐Andujar, Rafael</creatorcontrib><creatorcontrib>San Juan, Fernando</creatorcontrib><creatorcontrib>Montalva, Eva</creatorcontrib><creatorcontrib>Perez, Judith</creatorcontrib><creatorcontrib>Prieto, Martin</creatorcontrib><creatorcontrib>Berenguer, Marina</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Liver transplantation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Di Maira, Tommaso</au><au>Rubin, Angel</au><au>Puchades, Lorena</au><au>Aguilera, Victoria</au><au>Vinaixa, Carmen</au><au>Garcia, Maria</au><au>De Maria, Nicola</au><au>Villa, Erica</au><au>Lopez‐Andujar, Rafael</au><au>San Juan, Fernando</au><au>Montalva, Eva</au><au>Perez, Judith</au><au>Prieto, Martin</au><au>Berenguer, Marina</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Framingham score, renal dysfunction, and cardiovascular risk in liver transplant patients</atitle><jtitle>Liver transplantation</jtitle><addtitle>Liver Transpl</addtitle><date>2015-06</date><risdate>2015</risdate><volume>21</volume><issue>6</issue><spage>812</spage><epage>822</epage><pages>812-822</pages><issn>1527-6465</issn><eissn>1527-6473</eissn><coden>LITRFO</coden><abstract>Cardiovascular (CV) events represent major impediments to the long‐term survival of liver transplantation (LT) patients. The aim of this study was to assess whether the Framingham risk score (FRS) at transplantation can predict the development of post‐LT cardiovascular events (CVEs). Patients transplanted between 2006 and 2008 were included. Baseline features, CV risk factors, and CVEs occurring after LT (ischemic heart disease, stroke, heart failure, de novo arrhythmias, and peripheral arterial disease) were recorded. In total, 250 patients (69.6% men) with a median age of 56 years (range, 18‐68 years) were included. At transplantation, 34.4%, 34.4%, and 33.2% of patients, respectively, had a low, moderate, and high FRS with a median FRS of 14.9 (range, 0.09‐30); 14.4% of LT recipients developed at least 1 CVE at a median of 2.619 years (range, 0.006‐6.945 years). In the univariate analysis, factors associated with the development of CVEs were the continuous FRS at LT (P = 0.003), age (P = 0.007), creatinine clearance [estimated glomerular filtration rate (eGFR); P = 0.020], and mycophenolate mofetil use at discharge (P = 0.011). In the multivariate analysis, only the eGFR [hazard ratio (HR), 0.98; 95% confidence interval (CI), 0.97‐1.00; P = 0.009] and FRS (HR, 1.06; 95% CI, 1.02‐1.10; P = 0.002) remained in the model. Moreover, an association was also found between the FRS and overall survival (P = 0.004) with 5‐year survival rates of 82.5%, 77.8%, and 61.4% for the low‐, moderate‐, and high‐risk groups, respectively. Continuous FRS, eGFR, and hepatitis C virus infection were independent risk factors for overall mortality. In our series, the FRS and eGFR at LT were able to predict the development of post‐LT CVEs and poor outcomes. Liver Transpl 21:812‐822, 2015. © 2015 AASLD.</abstract><cop>United States</cop><pub>Wolters Kluwer Health, Inc</pub><pmid>27396823</pmid><doi>10.1002/lt.24128</doi><tpages>11</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1527-6465
ispartof Liver transplantation, 2015-06, Vol.21 (6), p.812-822
issn 1527-6465
1527-6473
language eng
recordid cdi_proquest_miscellaneous_1803452150
source MEDLINE; Wiley Online Library All Journals; Alma/SFX Local Collection
subjects Adolescent
Adult
Aged
Cardiovascular Diseases - diagnosis
Cardiovascular Diseases - epidemiology
Cardiovascular Diseases - mortality
Female
Glomerular Filtration Rate
Hepatitis C - epidemiology
Humans
Kaplan-Meier Estimate
Kidney - physiopathology
Kidney Diseases - diagnosis
Kidney Diseases - epidemiology
Kidney Diseases - mortality
Kidney Diseases - physiopathology
Liver Transplantation - adverse effects
Liver Transplantation - mortality
Logistic Models
Male
Middle Aged
Multivariate Analysis
Proportional Hazards Models
Retrospective Studies
Risk Assessment
Risk Factors
Spain - epidemiology
Time Factors
Transplant Recipients
Treatment Outcome
Young Adult
title Framingham score, renal dysfunction, and cardiovascular risk in liver transplant patients
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T10%3A04%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Framingham%20score,%20renal%20dysfunction,%20and%20cardiovascular%20risk%20in%20liver%20transplant%20patients&rft.jtitle=Liver%20transplantation&rft.au=Di%20Maira,%20Tommaso&rft.date=2015-06&rft.volume=21&rft.issue=6&rft.spage=812&rft.epage=822&rft.pages=812-822&rft.issn=1527-6465&rft.eissn=1527-6473&rft.coden=LITRFO&rft_id=info:doi/10.1002/lt.24128&rft_dat=%3Cproquest_cross%3E3694893571%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1683090688&rft_id=info:pmid/27396823&rfr_iscdi=true